Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | SCN1A | P35498 | 1/20 | 0.60 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21062177 | 1.00 | DRD4 (0.62) | DRD4SCN1ASCN5ASCN9AKCNH2 | |
| SCHEMBL19692513 | 0.89 | ATF4 (0.65) | DRD4SCN1ASCN5ASCN9AKCNH2 | |
| SCHEMBL19692579 | 0.89 | ATF4 (0.65) | DRD4SCN1ASCN5ASCN9AKCNH2 | |
| SCHEMBL19692512 | 0.89 | ATF4 (0.65) | DRD4SCN1ASCN5ASCN9AKCNH2 | |
| SCHEMBL24225699 | 0.85 | SCN1A (0.55) | DRD4SCN1ASCN5ASCN9AKCNH2 | |
| SCHEMBL21050195 | 0.85 | ATF4 (0.63) | SCN1ASCN5ASCN9AHTR7 | |
| SCHEMBL21062167 | 0.85 | ATF4 (0.63) | SCN1ASCN5ASCN9AHTR7 | |
| SCHEMBL20854550 | 0.83 | KCNH2 (0.62) | DRD4KCNH2CACNA1GLMNAMAPK1 | |
| SCHEMBL20854566 | 0.82 | DRD4 (0.66) | DRD4KCNH2CACNA1GLMNAMAPK1 | |
| SCHEMBL20854549 | 0.82 | DRD4 (0.66) | DRD4KCNH2CACNA1GLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11230542-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3723762-A2 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118785-A2 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190177310-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230542-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | DRD4 3659/4885SCN1A 4137/4885SCN5A 4169/4885 |
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | DRD4 3659/4885SCN1A 4137/4885SCN5A 4169/4885 |
| US-20190177310-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | DRD4 3659/4885SCN1A 4137/4885SCN5A 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.